The FDA released a new draft guidance on the clinical pharmacology data needed to support biosimilarity. Here's the guidance, and here's the announcement in the Federal Register.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.